Tumor-derived exosomes (TDEs) participate in formation and progression of different cancer
processes, including tumor microenvironment (TME) remodeling, angiogenesis, invasion …

Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

Cancer stem cells (CSCs), also known as tumor‐initiating cells (TICs), are suggested to be
responsible for drug resistance and cancer relapse due in part to their ability to self‐renew …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …

Ovarian cancer (OC) is one of the most common gynecologic tumors worldwide and one
with the highest mortality. Cisplatin (DDP) is the first platinum-based complex approved by …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Omics technologies have rapidly evolved with the unprecedented potential to shape
precision medicine. Novel omics approaches are imperative toallow rapid and accurate data …

Extracellular vesicles (EVs) are nano-sized, membranous structures secreted into the
extracellular space. They exhibit diverse sizes, contents, and surface markers and are …

Chemotherapeutic drugs are used to treat advanced stages of cancer or following surgery.
However, cancers often develop resistance against drugs, leading to failure of treatment and …